Immune dysregulation mediated by the oral microbiome: potential link to chronic inflammation and atherosclerosis

Journal of Internal Medicine

Volumn 280, Issue 1, 2016, Pages 114-128

  Slocum, C ^a   Kramer, C ^b   Genco, C A ^b  

^a Ora Inc   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; cardiovascular risk factors; immunity; infectious disease; inflammation; periodontal disease

Indexed keywords

TOLL LIKE RECEPTOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; ENDOTHELIUM CELL; HUMAN; IMMUNE DYSREGULATION; MOUTH FLORA; MOUTH INFECTION; NONHUMAN; PATHOGENESIS; PERIODONTAL DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION;

EID: 84975143308     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12476     Document Type: Review

References (115)

1. Reyes L, Eiler-McManis E, Rodrigues PH et al. Deletion of lipoprotein PG0717 in Porphyromonas gingivalis W83 reduces gingipain activity and alters trafficking in and response by host cells. PLoS One 2013; 8: e74230.
2. Eke PI, Dye BA, Wei L et al. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 2012; 91: 914–20.
3. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204–12.
4. Lockhart PB, Bolger AF, Papapanou PN et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association? A scientific statement from the American Heart Association. Circulation 2012; 125: 2520–44.
5. Bartova J, Sommerova P, Lyuya-Mi Y et al. Periodontitis as a risk factor of atherosclerosis. J Immunol Res 2014; 2014: 636893.
6. Oliver RC, Brown LJ, Löe H. Periodontal diseases in the United States population. J Periodontol 1998; 69: 269–78.
7. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005; 366: 1809–20.
8. Hayashi C, Gudino CV, Gibson FC III, Genco CA. REVIEW: Pathogen-induced inflammation at sites distant from oral infection: bacterial persistence and induction of cell-specific innate immune inflammatory pathways. Mol Oral Microbiol 2010; 25: 305–16.
9. Gibson FC, Yumoto H, Takahashi Y, Chou HH, Genco CA. Innate immune signaling and Porphyromonas gingivalis-accelerated atherosclerosis. J Dent Res 2006; 85: 106–21.
10. Hajishengallis G. Immune evasion strategies of Porphyromonas gingivalis. J Oral Biosci 2011; 53: 233–40.
11. Hajishengallis G. Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response. Trends Immunol 2014; 35: 3–11.
12. Hajishengallis G, Krauss JL, Liang S, McIntosh ML, Lambris JD. Pathogenic microbes and community service through manipulation of innate immunity. Adv Exp Med Biol 2012; 946: 69–85.
13. Abusleme L, Dupuy AK, Dutzan N et al. The subgingival microbiome in health and periodontitis and its relationship with community biomass and inflammation. ISME J 2013; 7: 1016–25.
14. Hajishengallis G, Liang S, Payne MA et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 2011; 10: 497–506.
15. Shaik-Dasthagirisaheb YB, Huang N, Gibson FC. Inflammatory response to Porphyromonas gingivalis partially requires interferon regulatory factor (IRF) 3. Innate Immun 2014; 20: 312–9.
16. Adamopoulos IE, Sabokbar A, Wordsworth BP, Carr A, Ferguson DJ, Athanasou NA. Synovial fluid macrophages are capable of osteoclast formation and resorption. J Pathol 2006; 208: 35–43.
17. Kurtiş B, Tüter G, Serdar M et al. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha in patients with chronic and aggressive periodontitis. J Periodontol 2005; 76: 1849–55.
18. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000; 71: 1535–45.
19. Edfeldt K, Swedenborg J, Hansson GK, Yan Z-Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158–61.
20. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508–19.
21. Cole JE, Georgiou E, Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm 2010; 2010: 1–18.
22. Feghali C, Wright T. Cytokines in acute and chronic inflammation. Front Biosci 1997; 2: 12–26. Available from: http://www.joponline.org.ezproxy.bu.edu/loi/jop (cited 2012 Jun. 14).
23. Hajishengallis G, Lambris JD. Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol 2011; 11: 187–200.
24. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675–80.
25. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3–9.
26. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 2010; 11: 373–84.
27. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011; 106: 858–67.
28. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158–61.
29. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993; 13: 1501–4.
30. Farsak B, Yildirir A, Akyön Y et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000; 38: 4408–11.
31. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000; 71: 1554–60.
32. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke 2001; 32: 385–91.
33. Latsios G, Saetta A, Michalopoulos NV, Agapitos E, Patsouris E. Detection of cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae DNA in carotid atherosclerotic plaques by the polymerase chain reaction. Acta Cardiol 2004; 59: 652–7.
34. Kozarov EV, Dorn BR, Shelburne CE, Dunn WA, Progulske-Fox A. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 2005; 25: e17–8.
35. Kaplan M, Yavuz SS, Cinar B et al. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis 2006; 10: 116–23.
36. Armstrong ML. Evidence of regression of atherosclerosis in primates and man. Postgrad Med J 1976; 52: 456–61.
37. St Clair RW. Atherosclerosis regression in animal models: current concepts of cellular and biochemical mechanisms. Prog Cardiovasc Dis 1983; 26: 109–32.
38. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.
39. Toomey S, Harhen B, Roche HM, Fitzgerald D, Belton O. Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 2006; 187: 40–9.
40. Francis AA, Pierce GN. An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp Clin Cardiol 2011; 16: 77–86.
41. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352–64.
42. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 2008; 5: 91–102.
43. Feig JE. Regression of atherosclerosis: insights from animal and clinical studies. Ann Glob Health 2014; 80: 13–23.
44. Björkegren JLM, Hägg S, Talukdar HA et al. Plasma cholesterol-induced lesion networks activated before regression of early, mature, and advanced atherosclerosis. PLoS Genet 2014; 10: e1004201.
45. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol 1996; 67(Suppl): 1123–37.
46. Genco RJ. Current view of risk factors for periodontal diseases. J Periodontol 1996; 67(Suppl): 1041–9.
47. Morrison HI, Ellison LF, Taylor GW. Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. J Cardiovasc Risk 1999; 6: 7–11.
48. Offenbacher S, Madianos PN, Champagne CM et al. Periodontitis-atherosclerosis syndrome: an expanded model of pathogenesis. J Periodontal Res 1999; 34: 346–52.
49. Amar S, Gokce N, Morgan S, Loukideli M, Van Dyke TE, Vita JA. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol 2003; 23: 1245–9.
50. Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J, Salomaa V. Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol 2007; 27: 1433–9.
51. Gibson FC, Ukai T, Genco CA. Engagement of specific innate immune signaling pathways during Porphyromonas gingivalis induced chronic inflammation and atherosclerosis. Front Biosci 2008; 13: 2041–59.
52. Seinost G, Wimmer G, Skerget M et al. Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis. Am Heart J 2005; 149: 1050–4.
53. Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT. Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study. Arch Intern Med 2000; 160: 2749–55.
54. Desvarieux M, Demmer RT, Rundek T et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005; 111: 576–82.
55. Kurita-Ochiai T, Yamamoto M. Periodontal pathogens and atherosclerosis: implications of inflammation and oxidative modification of LDL. Biomed Res Int 2014; 2014: 595981.
56. Rivera MF, Lee J-Y, Aneja M et al. Polymicrobial infection with major periodontal pathogens induced periodontal disease and aortic atherosclerosis in hyperlipidemic ApoE(null) mice. PLoS One 2013; 8: e57178.
57. Kebschull M, Demmer RT, Papapanou PN. “Gum bug, leave my heart alone!” – epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J Dent Res 2010; 89: 879–902.
58. Cannon CP, Braunwald E, McCabe CH et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646–54.
59. Grayston JT, Kronmal RA, Jackson LA et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637–45.
60. O'Connor CM, Dunne MW, Pfeffer MA et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459–66.
61. Jespersen CM, Als-Nielsen B, Damgaard M et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332: 22–7.
62. Reyes L, Herrera D, Kozarov E, Roldán S, Progulske-Fox A. Periodontal bacterial invasion and infection: contribution to atherosclerotic pathology. J Clin Periodontol 2013; 40(Suppl 14): S30–50.
63. Keizer HG. The “Mevalonate hypothesis”: a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids Health Dis 2012; 11: 149.
64. Raman K, Chong M, Akhtar-Danesh G-G et al. Genetic markers of inflammation and their role in cardiovascular disease. Can J Cardiol 2013; 29: 67–74.
65. Vita JA, Loscalzo J. Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 2002; 106: 164–6.
66. Gibson FC, Hong C, Chou H-H et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 2801–6.
67. Hayashi C, Madrigal AG, Liu X et al. Pathogen-mediated inflammatory atherosclerosis is mediated in part via toll-like receptor 2-induced inflammatory responses. J Innate Immun 2010; 2: 334–43.
68. Hayashi C, Papadopoulos G, Gudino CV et al. Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. J Immunol 2012; 189: 3681–8.
69. Slocum C, Coats SR, Hua N et al. Distinct lipid A moieties contribute to pathogen-induced site-specific vascular inflammation. PLoS Pathog 2014; 10: e1004215.
70. Naiki Y, Sorrentino R, Wong MH et al. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. J Immunol 2008; 181: 7176–85.
71. Kramer CD, Weinberg EO, Gower AC et al. Distinct gene signatures in aortic tissue from ApoE-/- mice exposed to pathogens or Western diet. BMC Genom 2014; 15: 1176.
72. Ieven MM, Hoymans VY. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Microbiol 2005; 43: 19–24.
73. Weiss SM, Roblin PM, Gaydos CA et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996; 173: 957–62.
74. Rafferty B, Jönsson D, Kalachikov S et al. Impact of monocytic cells on recovery of uncultivable bacteria from atherosclerotic lesions. J Intern Med 2011; 270: 273–80.
75. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. J Clin Periodontol 2006; 33: 401–7.
76. Tomás I, Diz P, Tobías A, Scully C, Donos N. Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. J Clin Periodontol 2012; 39: 213–28.
77. Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK. Bacteremia associated with toothbrushing and dental extraction. Circulation 2008; 117: 3118–25.
78. Bahrani-Mougeot FK, Paster BJ, Coleman S, Ashar J, Barbuto S, Lockhart PB. Diverse and novel oral bacterial species in blood following dental procedures. J Clin Microbiol 2008; 46: 2129–32.
79. Pujol C, Bliska JB. Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae. Clin Immunol 2005; 114: 216–26.
80. Moreau K, Lacas-Gervais S, Fujita N et al. Autophagosomes can support Yersinia pseudotuberculosis replication in macrophages. Cell Microbiol 2010; 12: 1108–23.
81. Zeituni AE, Jotwani R, Carrion J, Cutler CW. Targeting of DC-SIGN on human dendritic cells by minor fimbriated Porphyromonas gingivalis strains elicits a distinct effector T cell response. J Immunol 2009; 183: 5694–704.
82. Wang M, Shakhatreh MA, James D et al. Fimbrial proteins of Porphyromonas gingivalis mediate in vivo virulence and exploit TLR2 and complement receptor 3 to persist in macrophages. J Immunol 2007; 179: 2349–58.
83. Wang M, Hajishengallis G. Lipid raft-dependent uptake, signalling and intracellular fate of Porphyromonas gingivalis in mouse macrophages. Cell Microbiol 2008; 10: 2029–42.
84. Carrion J, Scisci E, Miles B et al. Microbial carriage state of peripheral blood dendritic cells (DCs) in chronic periodontitis influences DC differentiation, atherogenic potential. J Immunol 2012; 189: 3178–87.
85. Chou H-H, Yumoto H, Davey M et al. Porphyromonas gingivalis fimbria-dependent activation of inflammatory genes in human aortic endothelial cells. Infect Immun 2005; 73: 5367–78.
86. Takahashi Y, Davey M, Yumoto H, Gibson FC III, Genco CA. Fimbria-dependent activation of pro-inflammatory molecules in Porphyromonas gingivalis infected human aortic endothelial cells. Cell Microbiol 2006; 8: 738–57.
87. Dorn BR, Dunn WA, Progulske-Fox A. Porphyromonas gingivalis traffics to autophagosomes in human coronary artery endothelial cells. Infect Immun 2001; 69: 5698–708.
88. Qi M, Miyakawa H, Kuramitsu HK. Porphyromonas gingivalis induces murine macrophage foam cell formation. Microb Pathog 2003; 35: 259–67.
89. Glurich I, Grossi S, Albini B et al. Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol 2002; 9: 425–32.
90. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. PNAS 2012; 109: 594–9.
91. Wu X, Ma C, Han L et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010; 61: 69–78.
92. Koren O, Spor A, Felin J et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. PNAS 2011; 108(Suppl 1): 4592–8.
93. Craciun S, Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. PNAS 2012; 109: 21307–12.
94. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005; 106: 357–87.
95. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57–63.
96. Tang WHW, Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575–84.
97. Koeth RA, Wang Z, Levison BS et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576–85.
98. Gregory JC, Buffa JA, Org E et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 2015; 290: 5647–60.
99. Nakajima M, Arimatsu K, Kato T et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. PLoS One 2015; 10: e0134234.
100. Arimatsu K, Yamada H, Miyazawa H et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep 2014; 4: 4828.
101. Desvarieux M, Demmer RT, Jacobs DR, Papapanou PN, Sacco RL, Rundek T. Changes in clinical and microbiological periodontal profiles relate to progression of carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology study. J Am Heart Assoc 2013; 2: e000254.
102. Davis BK, Wen H, Ting JPY. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707–35.
103. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011; 41: 1203–17.
104. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241–7.
105. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007; 7: 31–40.
106. Taxman DJ, Huang MT, Ting JP. Inflammasome inhibition as a pathogenic stealth mechanism. Cell Host Microbe 2010; 8: 7–11.
107. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 339: 166–72.
108. Koné-Paut I, Piram M. Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: what did we learn? Autoimmun Rev 2012; 12: 77–80.
109. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597–605.
110. Cole JE, Mitra AT, Monaco C. Treating atherosclerosis: the potential of toll-like receptors as therapeutic targets. Expert Rev Cardiovasc Ther 2010; 8: 1619–35.
111. Michelsen KS, Wong MH, Shah PK et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679–84.
112. Leon CG, Tory R, Jia J, Sivak O, Wasan KM. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res 2008; 25: 1751–61.
113. Cole JE, Kassiteridi C, Monaco C. Toll-like receptors in atherosclerosis: a “Pandora's box” of advances and controversies. Trends Pharmacol Sci 2013; 34: 629–36.
114. Guo L, McLean JS, Yang Y et al. Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. PNAS 2015; 112: 7569–74.
115. Frias-Lopez J. Targeting specific bacteria in the oral microbiome. Trends Microbiol 2015; 23: 527–8.